Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10825397.2Aexternal-prioritypatent/EP2490533B1/en
Application filed by Amicus Therapeutics, Inc.filedCriticalAmicus Therapeutics, Inc.
Publication of CY1117258T1publicationCriticalpatent/CY1117258T1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Η παρούσα εφεύρεση παρέχει νέες συνθέσεις, καθώς και μεθόδους για την πρόληψη και/ή την θεραπευτική αγωγή διαταραχών λυσοσωμικής αποθήκευσης. Ειδικότερα, η παρούσα εφεύρεση παρέχει μεθόδους για την πρόληψη και/ή θεραπευτική αγωγή της νόσου Gaucher.The present invention provides novel compositions as well as methods for the prevention and / or treatment of lysosomal storage disorders. In particular, the present invention provides methods for the prevention and / or treatment of Gaucher disease.
CY20151101143T2009-10-192015-12-15
NEW COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF LYSOSOMIC STORAGE DISORDERS
CY1117258T1
(en)
Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348).